Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $930.000M-$945.000M to $980.000M-$995.000M vs $940.106M Est
Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $930.000 million-$945.000 million to $980.000 million-$995.000 million vs $940.106 million estimate.
Kiniksa thinks it will make more money next year than it said before—about $50 million more. When a company raises its sales prediction, it usually means business is going better than expected, which is a good signal to watch.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.